ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Vanda Pharmaceuticals and Novartis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Vanda PharmaceuticalsNovartis
studies on the registry823,900
open to participants now16211
phase 3 studies under way1294
reach primary completion within a year6125
programswith a study of their own in two years977+7 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseVanda PharmaceuticalsNovartis
Phase 100%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
Phase 2

Vanda Pharmaceuticals: 3 of its 9 programs at phase 2

  1. VSJ-110phase 2
  2. trichostatin Aphase 2
  3. VCA-894Aphase 2
33%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%
Phase 3

Vanda Pharmaceuticals: 4 of its 9 programs at phase 3

  1. tradipitantphase 3
  2. ponesimodphase 3
  3. milsaperidonephase 3
  4. VQW-765phase 3
44%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
Approved, new studies

Vanda Pharmaceuticals: 2 of its 9 programs at approved, new studies

  1. tasimelteonapproved, new study
  2. iloperidoneapproved, new study
22%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Vanda Pharmaceuticals3 readouts · 2 phase 3·

Vanda Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. VQW-765phase 3 · Dec 0 · NCT07221578
  2. tradipitantphase 3 · Dec 1 · NCT07446439
··

Vanda Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion

  1. VCA-894Aphase 2 · Mar 0 · NCT07223632
·······
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Vanda Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionVanda PharmaceuticalsNovartis
Dermatitis, Atopicboth · compare here

Vanda Pharmaceuticals in Dermatitis, Atopic: 1 program

  1. tradipitantphase 3

Their studies: Vanda Pharmaceuticals’ studies of Dermatitis, Atopic in search

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

Schizophreniaboth · compare here

Vanda Pharmaceuticals in Schizophrenia: 2 programs

  1. milsaperidonephase 3
  2. iloperidoneapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Schizophrenia in search

Novartis in Schizophrenia: 2 programs

  1. GXV-813phase 2
  2. XEP527phase 1

Their studies: Novartis’s studies of Schizophrenia in search

Hypertensionboth · compare here

Vanda Pharmaceuticals in Hypertension: 1 program

  1. iloperidoneapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Hypertension in search

Novartis in Hypertension: 2 programs

  1. QCZ484phase 2
  2. HJB647phase 1

Their studies: Novartis’s studies of Hypertension in search

Renal Insufficiencyboth · compare here

Vanda Pharmaceuticals in Renal Insufficiency: 1 program

  1. tasimelteonapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Renal Insufficiency in search

Novartis in Renal Insufficiency: 2 programs

  1. PKN605phase 2
  2. asciminibapproved, new study

Their studies: Novartis’s studies of Renal Insufficiency in search

Bronchiolitis Obliterans Syndromeboth · compare here

Vanda Pharmaceuticals in Bronchiolitis Obliterans Syndrome: 1 program

  1. ponesimodphase 3

Their studies: Vanda Pharmaceuticals’ studies of Bronchiolitis Obliterans Syndrome in search

Novartis in Bronchiolitis Obliterans Syndrome: 1 program

  1. asciminibapproved, new study

Their studies: Novartis’s studies of Bronchiolitis Obliterans Syndrome in search

Charcot-Marie-Tooth Diseaseboth · compare here

Vanda Pharmaceuticals in Charcot-Marie-Tooth Disease: 1 program

  1. VCA-894Aphase 2

Their studies: Vanda Pharmaceuticals’ studies of Charcot-Marie-Tooth Disease in search

Novartis in Charcot-Marie-Tooth Disease: 1 program

  1. EDK060phase 1

Their studies: Novartis’s studies of Charcot-Marie-Tooth Disease in search

Hematologic Neoplasmsboth · compare here

Vanda Pharmaceuticals in Hematologic Neoplasms: 1 program

  1. trichostatin Aphase 2

Their studies: Vanda Pharmaceuticals’ studies of Hematologic Neoplasms in search

Novartis in Hematologic Neoplasms: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Hematologic Neoplasms in search

Pruritusboth · compare here

Vanda Pharmaceuticals in Pruritus: 1 program

  1. tradipitantphase 3

Their studies: Vanda Pharmaceuticals’ studies of Pruritus in search

Novartis in Pruritus: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Pruritus in search

Psoriasisboth · compare here

Vanda Pharmaceuticals in Psoriasis: 1 program

  1. ponesimodphase 3

Their studies: Vanda Pharmaceuticals’ studies of Psoriasis in search

Novartis in Psoriasis: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Psoriasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Vanda Pharmaceuticals 4 of 9 · Novartis 56 of 77 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).